Stem Cell Clinic

Researchers Explore Hydrogels That Are Promising Materials For Delivering Therapeutic Cells – Texas A&M University

By Stell Cell Research

Electron micrograph showing ridges and grooves on MAP hydrogel microbeads caused by developing stem cells.

Courtsey of Daniel Alge

Baby diapers, contact lenses and gelatin dessert. While seemingly unrelated, these items have one thing in common theyre made of highly absorbent substances called hydrogels that have versatile applications. Recently, a type of biodegradable hydrogel, dubbed microporous annealed particle (MAP) hydrogel, has gained much attention for its potential to deliver stem cells for body tissue repair. But it is currently unclear how these jelly-like materials affect the growth of their precious cellular cargo, thereby limiting its use in regenerative medicine.

In a new study published in the November issue of Acta Biomaterialia, researchers at Texas A&M University have shown that MAP hydrogels, programmed to biodegrade at an optimum pace, create a fertile environment for bone stem cells to thrive and proliferate vigorously. They found the space created by the withering of MAP hydrogels creates room for the stem cells to grow, spread and form intricate cellular networks.

Our research now shows that stem cells flourish on degrading MAP hydrogels; they also remodel their local environment to better suit their needs, said Daniel Alge, assistant professor in the Department of Biomedical Engineering. These results have important implications for developing MAP hydrogel-based delivery systems, particularly for regenerative medicine where we want to deliver cells that will replace damaged tissues with new and healthy ones.

MAP hydrogels are a newer breed of injectable hydrogels. These soft materials are interconnected chains of extremely small beads made of polyethylene glycol, a synthetic polymer. Although the microbeads cannot themselves cling to cells, they can be engineered to present cell-binding proteins that can then attach to receptor molecules on the stem cells surface.

Once fastened onto the microbeads, the stem cells use the space between the spheres to grow and transform into specialized cells, like bone or skin cells. And so, when there is an injury, MAP hydrogels can be used to deliver these new cells to help tissues regenerate.

However, the health and behavior of stem cells within the MAP hydrogel environment has never been fully studied.

MAP hydrogels have superior mechanical and biocompatible properties, so in principle, they are a great platform to grow and maintain stem cells, Alge said. But people in the field really dont have a good understanding of how stem cells behave in these materials.

To address this question, the researchers studied the growth, spread and function of bone stem cells in MAP hydrogels. Alge and his team used three samples of MAP hydrogels that differed only in the speed at which they degraded, that is, either slow, fast or not at all.

First, for the stem cells to attach onto the MAP hydrogels, the researchers decorated the MAP hydrogels with a type of cell-binding protein. They then tracked the stem cells as they grew using a high-resolution, fluorescent microscope. The researchers also repeated the same experiment using another cell-binding protein to investigate if cell-binding proteins also affected stem cell development within the hydrogels.

To their surprise, Alges team found that for both types of cell-binding proteins, the MAP hydrogels that degraded the fastest had the largest population of stem cells. Furthermore, the cells were changing the shape of the MAP hydrogel as they spread and claimed more territory.

In the intact MAP hydrogel, we could still see the spherical microbeads and the material was quite undamaged, Alge said. By contrast, the cells were making ridges and grooves in the degrading MAP hydrogels, dynamically remodeling their environment.

The researchers also found that as the stem cells grew, the quantity of bone proteins produced by the growing stem cells depended on which cell-binding protein was initially used in the MAP hydrogel.

Alge noted that the insight gained through their study will greatly inform further research and development in MAP hydrogels for stem-cell therapies.

Although MAP hydrogel degradability profoundly affects the growth of the stem cells, we found that the interplay between the cell-binding proteins and the degradation is also important, he said. As we, as a field, make strides toward developing new MAP hydrogels for tissue engineering, we must look at the effects of both degradability and cell-binding proteins to best utilize these materials for regenerative medicine.

Other contributors to the research include Shangjing Xin from the Department of Biomedical Engineering at Texas A&M and Carl A. Gregory from the Institute for Regenerative Medicine at the Texas A&M Health Science Center.

This research was supported by funds from theNational Institute of Arthritis and Musculoskeletal and Skin Diseasesof the National Institutes of Health.

Link:
Researchers Explore Hydrogels That Are Promising Materials For Delivering Therapeutic Cells - Texas A&M University

Gill Aviation to Help Fund Blood Cancer Research – AviationPros.com

By Stell Cell Research

Gill Aviation has initiated a week-long campaign to raise awareness and help fund blood cancer research by donating a portion of fuel sales to the Leukemia & Lymphoma Society (LLS).

From February 3-7, Gill Aviation will donate 5 cents for every gallon of Jet A fuel sold. In addition, donations can be made on-line through a special LLS web page created by Kya Gill, a Houston, Texas high school student, in honor of her sister Paige who underwent treatment for Lymphoma. The goal is to raise $250,000 during the campaign period.

We are very proud of our daughter Kya and her efforts to help fund blood cancer research to fight Leukemia and Lymphoma, two of the most common forms of cancer in children, teens and young adults, said Jag Gill, President of Gill Aviation. We have selected to work with LLS because the research they do provides a gateway to curing these cancers through advanced treatments such as chemotherapy, radiation and stem cell transplantation.

Read the original here:
Gill Aviation to Help Fund Blood Cancer Research - AviationPros.com

Two Day Conference on Cell Therapy Bioprocessing (Boston, MA, United States – June 25-26, 2020) – Gain Insight into the Latest Advancements and…

By Stell Cell Research

DUBLIN, Feb. 4, 2020 /PRNewswire/ -- The "2nd Annual Cell Therapy Bioprocessing Conference" conference has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. There are factors like manufacturing maze, investment, logistics and regulatory challenges which prevents cell and gene therapies being widely used.

A unique platform to provide the exact solutions to these robust manufacturing and bioprocessing challenges is presented at the 2nd Annual Cell Therapy Bioprocessing Conference, taking place at Boston-USA on 25th & 26th June 2020.

Key Highlights

Why Attend

Who Should Attend:

From Therapeutics and Pharmaceuticals, Cell & Gene therapy-based companies:

Engineers/ Scientists/ Researchers/ Project leaders in:

Agenda:

Day 1: Thursday June 25th

CELL CULTURE TO CELL THERAPY

CELL THERAPY BIOPROCESSING AND DEVELOPMENT

PROCESS MONITORING & QUALITY CONTROL

Day 2: Friday June 26th

LOGISTICS, REGULATORY & INVESTMENT

Speakers:

For more information about this conference visit https://www.researchandmarkets.com/r/z4ezsr

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/two-day-conference-on-cell-therapy-bioprocessing-boston-ma-united-states---june-25-26-2020---gain-insight-into-the-latest-advancements-and-opportunities-in-the-cell-gene-therapy-manufacturing-area-300998633.html

SOURCE Research and Markets

The rest is here:
Two Day Conference on Cell Therapy Bioprocessing (Boston, MA, United States - June 25-26, 2020) - Gain Insight into the Latest Advancements and...

Global Viral Inactivation Market Analysis 2016 to 2026 – Market Expected to Reach $1,209.17 Million by 2026 – ResearchAndMarkets.com – Yahoo Finance

By Stell Cell Research

The "Global Viral Inactivation Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Viral Inactivation market is expected to reach $1,209.17 million by 2026 growing at a CAGR of 14.2% from 2018 to 2026.

Factors such as increasing government support for pharmaceutical and biotechnology industries, an increase in the number of drug launches & approvals and rising investment in the life sciences sector are driving the market growth. Though, high cost of biologics and biosimilar products development & manufacturing restrain the market growth.

Based on the product, Kits and reagents are expected to have a lucrative growth during the forecast period due to their continuous usage by pharmaceutical and biopharmaceutical companies. With an increase in the number of pharmaceutical and biopharmaceutical companies and the rise in R&D spending for the purpose of new drug development, the usage of kits and reagents has increased tremendously.

Key Questions Answered in this Report:

The key vendors mentioned are Merck KGAA, Cerus Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corporation, Texcell, Inc., Parker Hannifin Corporation, Sanofi SA, SGS SA, Invitrogen Corp., General Electric Co., Rad Source Technologies, Qiagen NV, ZeptoMetrix Corp., MockV Solutions, Vironova AB, Viral Inactivated Plasma Systems SA, and BioReliance.

Key Questions Answered in this Report:

Key Topics Covered:

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Viral Inactivation Market, By Product

5.1 Introduction

5.2 Services

5.3 Viral Inactivation Systems and Accessories

5.4 Kits and Reagents

6 Global Viral Inactivation Market, By Method

6.1 Introduction

6.2 Pasteurization

6.3 Solvent Detergent Method

6.4 Other Methods

7 Global Viral Inactivation Market, By Application

7.1 Introduction

7.2 Blood and Blood Products

7.3 Tissues and Tissue Products

7.4 Vaccines and Therapeutics

7.5 Stem Cell Products

7.6 Cellular and Gene Therapy Products

8 Global Viral Inactivation Market, By End User

8.1 Introduction

8.2 Pharmaceutical and Biotechnology Companies

8.3 Academic Research Institutes

8.4 Contract Research Organizations

8.5 Blood Banks and Hospitals

9 Global Viral Inactivation Market, By Geography

9.1 Introduction

9.2 North America

9.3 Europe

9.4 Asia Pacific

9.5 South America

9.6 Middle East & Africa

10 Strategic Benchmarking

11 Vendors Landscape

11.1 Merck KGAA

11.2 Cerus Corporation

11.3 Thermo Fisher Scientific Inc.

11.4 Sartorius AG

11.5 Danaher Corporation

11.6 Texcell, Inc.

11.7 Parker Hannifin Corporation

11.8 Sanofi SA

11.9 SGS SA

11.10 Invitrogen Corp.

11.11 General Electric Co.

11.12 Rad Source Technologies

11.13 Qiagen NV

11.14 ZeptoMetrix Corp.

11.15 MockV Solutions

11.16 Vironova AB

11.17 Viral Inactivated Plasma Systems SA

11.18 BioReliance

For more information about this report visit https://www.researchandmarkets.com/r/m0wcqb

View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005900/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Follow this link:
Global Viral Inactivation Market Analysis 2016 to 2026 - Market Expected to Reach $1,209.17 Million by 2026 - ResearchAndMarkets.com - Yahoo Finance

Biologics Safety Testing Market Will Be Hit $ 4.8 Billion By 2026 – Story of Future

By Stell Cell Research

The global Biologics Safety Testing Market is anticipated to grow at a constant CAGR around 11.7% from 2019 to 2026 and the market value reach around US$ 4.8 billion by 2026.

According to a new report by Acumen Research and Consulting, Recently published report titled Biologics Safety Testing Market Global Industry Analysis, Market Size, Opportunities and Forecast, 2019-2026. This report also covers details of market size, growth spectrum, and the competitive scenario of the Biologics Safety Testing Market in the forecast era.

Recent global market survey Biologics Safety Testing Market involves various industry organizations from different geographies to generate a report of more than 100 pages. The study is an optimal combination of quality and quantitative data which illustrates major market trends, challenges facing by industry and company, as well as gap analysis and new opportunities with trends on this market. The research links historical data for 2015-2018 and forecasts up to 2026. The objective of this research is to present an application; type and geographical region evaluation of the worldwide Biologics Safety Testing Market Regions include North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

Click To Get>>>FREE SAMPLE PDF (Including Full TOC, Table & Figures)

Biologics Safety Testing Market (By Product Type: Kits & Reagents, Instruments; By Application: Blood and Blood-related Products Testing, Vaccine and Therapeutics Development, Cellular and Gene Therapy, Tissue and Tissue-related Products Testing, Stem Cell Research; By Test Type: Endotoxin Tests, Sterility Tests, Cell Line Authentication and Characterization Tests, Residual Host Contamination Detection Tests, Adventitious Agent Detection Tests, Bioburden tests, Other) Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 2026

The research is also aimed at delivering the recent market intelligence and helping decision makers make sound investment evaluations, as well as defining and analysing changing trends and key drivers, challenges & opportunities. We have also implemented significant company rivals who penetrate the global Biologics Safety Testing Market with major strategies and competitive landscape to evaluate the situation of players currently. The study also identifies the qualitative effect on market segmentation and geographical regions of distinct market variables. Thus, the research builds the attractiveness of each important segment over the forecast period.

This research includes a thorough 360-degree analysis on this market, which provides insight into possibilities and difficulties for the stakeholders. It monitors the worldwide Biologics Safety Testing Market in developed economies and provides detailed comment and precise quantitative insight. The research also involves incisive competitive landscape analyses and offers important market players suggestions on effective imperatives and strategies.

Scope of the Report:

The report first uses historic data from different companies. The data collected is used to analyses the growth of industries in the past years. It includes data from the year 2015 to the year 2018. The forecast data provides the reader with an understating of the future of the market. The same data is used to predict the expectation of the companies and how they are expected to evolve in the coming years. The research provides historical as well as estimated data from the year 2019 to 2026. The details in the report give a brief overview of the market by examining its historical data, the current data, and forecast data to understand the growth of the market.

Competitive Landscape

The competition witnessed in the market is soaring. With rising demand for innovation, players are experimenting with various strategies to gain competitive edge and strengthen their foothold in the market. Several companies operating in the industry are looking at expanding their footprint across emerging nations to capitalize on the prevailing opportunities there. The gap in demand and supply of healthcare facilities in underdeveloped countries has resulted in the presence of unmet demand in these countries. These companies are looking at capitalizing on this to emerge at the fore of the global market.

Growth strategies adopted by the companies operating in the market are examined in detail. This is done to study how these strategies influence on this market. Furthermore, the bargaining power of suppliers and buyers. Furthermore, it reveals threat from new entrants and available substitute products.

Key Players & Strategies

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market. The Biologics Safety Testing Market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues.

Some major players in the Intelligent Intravenous Infusion Pumps Market include Charles River Laboratories, SGS SA, Lonza Group LTD, Merck KGaA, and WuXi Apptec, Thermo Fisher Scientific Inc., Sartorius AG, Cytovance Biologics, Inc., Pace Analytical Services Inc., Eurofins Scientific Se, Avance Biosciences Inc., Source Bioscience, and Toxikon Corporation among others.

Market Segmentation

Market By Product Type

Market By Application

Market By Test Type

Market By Geography

Key Takeaways:

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com| +1 407 915 4157

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW1.1. Definition and Scope1.1.1. Definition of Biologics Safety Testing1.1.2. Market Segmentation1.1.3. List of Abbreviations1.2. Summary1.2.1. Market Snapshot1.2.2. Biologics Safety Testing Market By Application1.2.2.1. Global Biologics Safety Testing Market Revenue and Growth Rate Comparison By Application (2015-2026)1.2.2.2. Global Biologics Safety Testing Market Revenue Share By Application in 20171.2.2.3. Vaccine and Therapeutics Development1.2.2.4. Blood and Blood-related Products Testing1.2.2.5. Cellular and Gene Therapy1.2.2.6. Tissue and Tissue-related Products Testing1.2.2.7. Stem Cell Research1.2.3. Biologics Safety Testing Market By Product Type1.2.3.1. Global Biologics Safety Testing Market Revenue and Growth Rate Comparison By Product Type (2015-2026)1.2.3.2. Global Biologics Safety Testing Market Revenue Share By Product Type in 20171.2.3.3. Kits & Reagents1.2.3.4. Instruments1.2.4. Biologics Safety Testing Market By Test Type1.2.4.1. Global Biologics Safety Testing Market Revenue and Growth Rate Comparison By Test Type (2015-2026)1.2.4.2. Global Biologics Safety Testing Market Revenue Share By Test Type in 20171.2.4.3. Sterility Tests1.2.4.4. Endotoxin Tests1.2.4.5. Cell Line Authentication and Characterization Tests1.2.4.6. Residual Host Contamination Detection Tests1.2.4.7. Adventitious Agent Detection Tests1.2.4.8. Bioburden tests1.2.4.9. Others1.2.5. Biologics Safety Testing Market By Geography1.2.5.1. Global Biologics Safety Testing Market Revenue and Growth Rate Comparison by Geography (2015-2026)1.2.5.2. North America Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)1.2.5.3. Europe Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)1.2.5.4. Asia-Pacific Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)1.2.5.5. Latin America Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)1.2.5.6. Middle East and Africa (MEA) Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS2.1. Market Drivers2.2. Restraints and Challenges2.3. Growth Opportunities2.4. Porters Five Forces Analysis2.4.1. Bargaining Power of Suppliers2.4.2. Bargaining Power of Buyers2.4.3. Threat of Substitute2.4.4. Threat of New Entrants2.4.5. Degree of Competition2.5. Value Chain Analysis2.6. Cost Structure Analysis2.6.1. Raw Material and Suppliers2.6.2. Manufacturing Process Analysis2.7. Regulatory Compliance2.8. Competitive Landscape, 20172.8.1. Player Positioning Analysis2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS3.1. Capacity and Commercial Production Date of Global Biologics Safety Testing Major Manufacturers in 20173.2. Manufacturing Plants Distribution of Global Biologics Safety Testing Major Manufacturers in 20173.3. R&D Status and Technology Source of Global Biologics Safety Testing Major Manufacturers in 20173.4. Raw Materials Sources Analysis of Global Biologics Safety Testing Major Manufacturers in 2017

CHAPTER 4. BIOLOGICS SAFETY TESTING MARKET BY APPLICATION4.1. Global Biologics Safety Testing Revenue By Application4.2. Vaccine and Therapeutics Development4.2.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.2.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)4.3. Blood and Blood-related Products Testing4.3.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.3.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)4.4. Cellular and Gene Therapy4.4.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.4.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)4.5. Tissue and Tissue-related Products Testing4.5.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.5.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)4.6. Stem Cell Research4.6.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.6.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)

CHAPTER 5. BIOLOGICS SAFETY TESTING MARKET BY PRODUCT TYPE5.1. Global Biologics Safety Testing Revenue By Product Type5.2. Kits & Reagents5.2.1. Market Revenue and Growth Rate, 2015 2026 ($Million)5.2.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)5.3. Instruments5.3.1. Market Revenue and Growth Rate, 2015 2026 ($Million)5.3.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)

CHAPTER 6. BIOLOGICS SAFETY TESTING MARKET BY TEST TYPE6.1. Global Biologics Safety Testing Revenue By Test Type6.2. Sterility Tests6.2.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.2.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.3. Endotoxin Tests6.3.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.3.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.4. Cell Line Authentication and Characterization Tests6.4.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.4.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.5. Residual Host Contamination Detection Tests6.5.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.5.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.6. Adventitious Agent Detection Tests6.6.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.6.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.7. Bioburden tests6.7.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.7.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.8. Others6.8.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.8.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)

CHAPTER 7. NORTH AMERICA BIOLOGICS SAFETY TESTING MARKET BY COUNTRY7.1. North America Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)7.2. North America Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)7.3. U.S.7.3.1. U.S. Biologics Safety Testing Market Revenue and Forecast By Application, 2015 2026 ($Million)7.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)7.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)7.4. Canada7.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)7.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)7.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 8. EUROPE BIOLOGICS SAFETY TESTING MARKET BY COUNTRY8.1. Europe Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)8.2. Europe Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)8.3. UK8.3.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)8.4. Germany8.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)8.5. France8.5.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.5.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.5.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)8.6. Spain8.6.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.6.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.6.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)8.7. Rest of Europe8.7.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.7.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.7.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC BIOLOGICS SAFETY TESTING MARKET BY COUNTRY9.1. Asia-Pacific Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)9.2. Asia-Pacific Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)9.3. China9.3.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.4. Japan9.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.5. India9.5.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.5.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.5.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.6. Australia9.6.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.6.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.6.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.7. South Korea9.7.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.7.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.7.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.8. Rest of Asia-Pacific9.8.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.8.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.8.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 10. LATIN AMERICA BIOLOGICS SAFETY TESTING MARKET BY COUNTRY10.1. Latin America Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)10.2. Latin America Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)10.3. Brazil10.3.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)10.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)10.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)10.4. Mexico10.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)10.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)10.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)10.5. Rest of Latin America10.5.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)10.5.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)10.5.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 11. MIDDLE EAST & AFRICA BIOLOGICS SAFETY TESTING MARKET BY COUNTRY11.1. Middle East & Africa Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)11.2. Middle East & Africa Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)11.3. GCC11.3.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)11.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)11.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)11.4. Saudi Africa11.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)11.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)11.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)11.5. Rest of Middle East & Africa11.5.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)11.5.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)11.5.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 12. COMPANY PROFILE12.1. Charles River Laboratories12.1.1. Company Snapshot12.1.2. Overview12.1.3. Financial Overview12.1.4. Product Portfolio12.1.5. Key Developments12.1.6. Strategies12.2. SGS SA12.2.1. Company Snapshot12.2.2. Overview12.2.3. Financial Overview12.2.4. Product Portfolio12.2.5. Key Developments12.2.6. Strategies12.3. Lonza Group LTD12.3.1. Company Snapshot12.3.2. Overview12.3.3. Financial Overview12.3.4. Product Portfolio12.3.5. Key Developments12.3.6. Strategies12.4. Merck KGaA12.4.1. Company Snapshot12.4.2. Overview12.4.3. Financial Overview12.4.4. Product Portfolio12.4.5. Key Developments12.4.6. Strategies12.5. WuXi Apptec12.5.1. Company Snapshot12.5.2. Overview12.5.3. Financial Overview12.5.4. Product Portfolio12.5.5. Key Developments12.5.6. Strategies12.6. Thermo Fisher Scientific Inc.12.6.1. Company Snapshot12.6.2. Overview12.6.3. Financial Overview12.6.4. Product Portfolio12.6.5. Key Developments12.6.6. Strategies12.7. Sartorius AG12.7.1. Company Snapshot12.7.2. Overview12.7.3. Financial Overview12.7.4. Product Portfolio12.7.5. Key Developments12.7.6. Strategies12.8. Cytovance Biologics, Inc.12.8.1. Company Snapshot12.8.2. Overview12.8.3. Financial Overview12.8.4. Product Portfolio12.8.5. Key Developments12.8.6. Strategies12.9. Pace Analytical Services Inc.12.9.1. Company Snapshot12.9.2. Overview12.9.3. Financial Overview12.9.4. Product Portfolio12.9.5. Key Developments12.9.6. Strategies12.10. Eurofins Scientific Se12.10.1. Company Snapshot12.10.2. Overview12.10.3. Financial Overview12.10.4. Product Portfolio12.10.5. Key Developments12.10.6. Strategies12.11. Avance Biosciences Inc.12.11.1. Company Snapshot12.11.2. Overview12.11.3. Financial Overview12.11.4. Product Portfolio12.11.5. Key Developments12.11.6. Strategies12.12. Source Bioscience12.12.1. Company Snapshot12.12.2. Overview12.12.3. Financial Overview12.12.4. Product Portfolio12.12.5. Key Developments12.12.6. Strategies12.13. Toxikon Corporation12.13.1. Company Snapshot12.13.2. Overview12.13.3. Financial Overview12.13.4. Product Portfolio12.13.5. Key Developments12.13.6. Strategies12.14. Others12.14.1. Company Snapshot12.14.2. Overview12.14.3. Financial Overview12.14.4. Product Portfolio12.14.5. Key Developments12.14.6. Strategies

CHAPTER 13. RESEARCH APPROACH13.1. Research Methodology13.1.1. Initial Data Search13.1.2. Secondary Research13.1.3. Primary Research13.2. Assumptions and Scope

Buy this Premium Research Report@https://www.acumenresearchandconsulting.com/buy-now/0/1656

The report is readily available and can be dispatched immediately after payment confirmation.

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Contact Us:

Saurabh S.Phone: +14079154157 | +14089009135Email: sales@acumenresearchandconsulting.comWebsite:https://www.acumenresearchandconsulting.comFollow Us:LinkedIN |Twitter

See more here:
Biologics Safety Testing Market Will Be Hit $ 4.8 Billion By 2026 - Story of Future

Korzan: On World Cancer day, pledge to be relentless – AberdeenNews.com

By Stem Cell Clinic

The Center for Disease Control and Prevention has projected that 1.9 million people in the United States and 18 million around the world will be diagnosed with cancer in 2020.

In small town family practices and big city hospitals all across America and around the world, doctors will give these patients the news that they have cancer and tell them to go home and get their affairs in order before starting treatment.

When somebody is told they have cancer, it hits them like a body blow. Theres fear. Its real. Its raw. After the initial shock and terror of being diagnosed with cancer, these folks will leave the doctors office in a daze and go home.

There will be scary, sleepless nights. Floors will be paced. There will be emotional phone calls where words cannot even begin to describe the hurt on the other end of the line as the cancer diagnosis is shared with a parent or a sibling or a child.

On top of being sick, theres financial stress. Anxious conversations around the kitchen table about money. What happens with work? The mortgage still has to be paid. Bills start pile up as the first insurance co-pays come due. There are questions about a living will and life insurance.

Friends and relatives will flood social media with messages of thoughts and prayers and fill up mailboxes with cards. There will be flowers from loved ones. But in the middle of the night, alone with their thoughts, the silence will be deafening.

The day will finally come when the person checks into a cancer center, puts on a hospital gown and officially becomes a patient. In almost all cases they start receiving some form of chemotherapy or radiation. Many times the treatment will be worse than the actual disease, ultimately proving to be a therapeutic failure.

A cancer patient can push the call button and the nurse will bring medication for nausea or diarrhea or other common side effects of treatment. Pain pills and depression meds may be prescribed. A social worker or chaplain might be summoned.

The problem is theres no magic pill to inspire courage. Nothing can be prescribed to power the patient forward to face another challenging day of treatment. This is the ultimate battle for survival. To live they must will themselves forward. The fight is not just physical. The fight is mental. Its all mindset.

How do I know so much about cancer at age 13? My perspective is personal. My dad was diagnosed with acute myeloid leukemia in 2012. For half my life, Ive watched him battle this dreadful, deadly disease as it relapsed after his initial treatment, and then relapsed a second time.

After riding an emotional rollercoaster of devastating lows and euphoric highs that spanned five years and 11 rounds of intensive chemotherapy, the experience ultimately culminated with my father beating the disease after undergoing a high-risk stem cell transplant at the Mayo Clinic in Rochester, Minn.

I remember asking my dad during an especially tough round of chemotherapy that just crushed him, How can you suffer this much and still be so strong? Ill never forget his answer: Floyd, there may come a time in your life when the only one left who believes in you is you. In those times, you have to will yourself forward. You have to be relentless.

The message was so powerful I remember getting goose bumps at the time. I was so moved by my dads relentless mindset and how it helped him to battle cancer that I wanted to share it to help others. On the anniversary of my dads successful transplant, I started the Relentless Pledge, a nonprofit organization.

Working with hospital administrators and oncology nurses in South Dakota, North Dakota and all across America, were working to give each cancer patient a relentless wristband to inspire hope and courage. In that moment, the patient knows they are not alone in the fight against cancer. They know you and I and a million other Americans have their back.

For more information, and to take the pledge to be relentless in your own life and support the mission of the Relentless Pledge organization on World Cancer Day, which is today, you can visit our website at relentlesspledge.org online.

Floyd Korzan, 13, of Mitchell, started the Relentless Pledge organization, which aims to give each cancer patient in South Dakota and across the nation a relentless wristband to inspire hope and courage. For more information, visit relentlesspledge.org. This column is being run on World Cancer Day.

Read the rest here:
Korzan: On World Cancer day, pledge to be relentless - AberdeenNews.com

Global Radiation Therapy Market to Reach US$ 8.6 bn by 2026, Product Approvals to Drive Growth: Transparency Market Research – PRNewswire

By Stem Cell Clinic

ALBANY, New York, Feb. 4, 2020 /PRNewswire/ -- Amid technological advancement, and notable research and development activities, the global radiation therapy marketis set to chart a sturdy growth curve, owing to a steady growth rate of 5.2% from 2018 to 2026. As per Transparency Market Research (TMR), the growth is attributable to surge in product approvals, increase in expenditure on healthcare, high incidence of cancer, and a growing preference for non-invasive treatment procedures.

TMR states that, "From bench to clinic, there is a wave of therapeutic and diagnostic technologies, paving way for higher growth in oncology. And, this will aid radiation therapy witness better times to come. Over the forecast period external beam radiation therapy will dominate the market landscape."

Key Findings of the Radiation Therapy Market Study

Explore 183 pages of top-notch research, incisive insights, and detailed country-level projections. Gain business intelligence on radiation therapy market by Type - External Beam Radiation Therapy (Conformal Radiation Therapy, Proton Beam Therapy, Image Guided Radiation Therapy, Stereotactic Radiation Therapy), Internal Radiation Therapy (Brachytherapy, Systemic Radiation Therapy); End user - Hospitals, Specialty Clinics. https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=36080

Radiation Therapy Market: Key Driving Factors

The market report, based on extensive research, by Transparency Market Research, is leading to growth in the landscape. And, a wave of innovation is keeping the statistics buoyant over the period. Some of the factors that will sustain growth over the forecast period in the global radiation therapy market include the following:

View Detailed Table of Contents athttps://www.transparencymarketresearch.com/report-toc/36080

Key Impediments for Radiation Therapy Market Players

While the overall outlook of the global radiation therapy market is positive, TMR speaks of certain restraints that will hamper growth to some extent. According to the study, the key restraints impeding market growth include,

Radiation Therapy Market: Region-wise Analysis

Analyze radiation therapy market growth in 30+ countries including US, Canada, Germany, United Kingdom, France, Italy, Russia, Poland, Benelux, Nordic, China, Japan, India, and South Korea. Request a sampleof the study,

Competition Landscape

Strategic alliances and a keen focus on technological advancement is the key to growth for players operating in the global radiation therapy market over the forecast period. One of the most notable agreement that took place in the recent past November 2018 is that between Chengdu Xingcheng and Mevion. The aim behind the move is to lead center for proton therapy in China's sub-provincial city Chengdu.

Besides, players are focused on product development and launch. For instance, in the year 2018, ProBeam 360 a system of single room proton therapy - was launched by Varian Medical Systems. In the same year Hitachi Ltd. received approval for commercialization of RGPT.

Key players include Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuray Incorporated (US), Ion Beam Applications SA (Belgium), ViewRay, Inc. (US), IsoRay Medical, Inc. (US), Hitachi Ltd. (Japan), Panacea Medical Technologies Pvt. Ltd. (India), Provision Healthcare (US), and Mevion Medical Systems, Inc. (US)

Transparency Market Research has segmented the radiation therapy market report based on type, end-use and region.

By Type:

External beam Radiation Therapy

Internal Radiation Therapy

By End user:

Explore Transparency Market Research's award-winning coverage of the global Pharmaceutical industry:

External Beam Radiation Therapy Market- External beam radiation therapy is the most common type of radiation therapy used in cancer treatments around the world. During the therapy, high-intensity radiation beams form a linear accelerator are focused on the tumor. Major drivers of the global external beam radiation therapy market are increase in patient population, new product approvals, technological advancements, favorable reimbursement policies, and rise in health care expenditure in developing economies such as India and others.

Proton Therapy Market- Rise in prevalence of cancer patients, growing awareness among people, improvement in insurance coverage for proton therapy, increase in consumption of tobacco, and surge in demand for proton therapy are factors driving the global proton therapy market. Tobacco use is associated with increased risk of several cancers including lung, oral cavity, pharynx, bladder, esophagus, kidney, liver, stomach, larynx, pancreas, bowel, cervix, leukemia, and ovarian.

Cancer Biomarkers Market- The global cancer biomarkers market is expected to exhibit a splendid CAGR of 11.8% during the forecast period from 2017 to 2025. In this timeframe, the market is anticipated to gain revenue worth US$27.63 bn by the end of 2025. Increasing incidences of various types of cancers all over the globe has caused a rise in the need for cancer biomarkers, thereby providing a healthy impetus to the associated market.

Cancer Cachexia Market- The cancer cachexia market stood at US$1.63 bn and is projected to garner a CAGR of 4.90% from 2017 to 2025. By the end of this assessment period, opportunities in the market will climb to US$2.51 bn. The growth of the global cancer cachexia market is fueled by vast research on using multiple agents for treating metabolic abnormalities in cachexia. Development of these multiple pharmacologic agents will further gather steam on the back of regulatory landscape.

Stem Cells Market- the global market for stem cells is projected to reach a value of US$270.5 bn by the end of 2025. The market is likely to exhibit a strong 13.80% CAGR between 2017 and 2025. The rapid development of the infrastructure that is required for the stem cell banking and processing, especially in developing economies is predicted to encourage the growth of the global stem cells market in the coming years.

Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor's moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage's actionable insights and remove the guesswork in making colossal decisions.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key tohelp enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: http://www.transparencymarketresearch.com

SOURCE Transparency Market Research

Originally posted here:
Global Radiation Therapy Market to Reach US$ 8.6 bn by 2026, Product Approvals to Drive Growth: Transparency Market Research - PRNewswire

SASpine to offer Stem Cell Therapy – Yahoo Finance

By Stem Cell Clinic

SAN ANTONIO, Feb. 3, 2020 /PRNewswire/ -- SASpine is now offering cutting edge Stem Cell Treatments to patients. For the past several years Dr. Steven Cyr, Mayo Clinic Trained Spine Surgeon, has been researching the benefits of stem cells in the treatment of multiple medical conditions including spinal disorders, specifically, conditions which involve spinal cord injury, degenerative disc disease, herniated discs, and as a supplement to enhance the success of Spinal fusions when treating instability, deformity, and fractures of the spine.

Steven J. Cyr, M.D., is a spine surgeon who has gained a reputation for surgical excellence in Texas, throughout the nation, and abroad.

Dr. Steven Cyr has been treating patients using growth factors and stem cells contained in amniotic tissue and bone marrow aspirate to provide a potential for improved success with fusion procedures, when treating herniated discs, and for arthritic or damaged joints, with remarkable success. "The goal of any medical intervention is to yield improved outcomes with the ideal result of returning a patient to normal function, when possible," states Dr Cyr. He went on to elaborate that there are times when only a structural solution can solve problems related to spinal disorders, but even in that scenario, the use of stem cells or growth factors derived from stem cell products can possibly improve the success of surgical procedures. "I have patients previously unable to jog or run return to normal function and athletic ability after injections of growth factors and stem cell products into the knee joints, hip joints, and shoulder joints," he said. "This includes high-level athletes, professional dancers, and the average weekend warrior."

There may be promise in treating patients with spinal cord injury as well. SASpine CEO, LeAnn Cyr, states, "There are reports of patients gaining significant neurological improvement after being treated with stem cells." Dr Cyr continues, "Most patients with spinal cord injuries resulting from trauma also have mechanical pressure on the nerves that result either from bone fragments or disc material compressing the spinal cord that needs to be removed along with surgical stabilization of the spinal bones. There's significant potential that stem cells bring to the equation when treating these types of patients, and I am excited about the potential that these products offer to the host of treatments to address spinal conditions and arthritic joints."

For more information about SASpine's Stem Cell Treatment Program, visit http://www.saspine.com or call (210) 487-7463 in San Antonio or (832) 919-7990 in Houston.

Related Linkswww.facebook.com/saspinewww.instagram.com/surgical.associates.in.spine

If you've been living with back pain, you're not alone. Here at SASpine, we have experienced spine specialists who are committed to improving your quality of life. (PRNewsfoto/SASpine)

View original content to download multimedia:http://www.prnewswire.com/news-releases/saspine-to-offer-stem-cell-therapy-300997355.html

SOURCE SASpine

See the original post here:
SASpine to offer Stem Cell Therapy - Yahoo Finance

Dr. Kenneth Pettine Announces Verification of Clinical Safety Trial – Yahoo Finance

By Stem Cell Clinic

Kenneth Pettine's stem cell product to treat OA was tested on retired Navy SEALs

FORT COLLINS, CO / ACCESSWIRE / February 3, 2020 / Kenneth Pettine is proud to announce that his revolutionary mesenchymal stem cell product to treat osteoarthritis was recently tested on 33 former Navy SEALs (one is a medal of honor recipient).

Kenneth Pettine is co-founder of Paisley Laboratories and a co-developer of a bone marrow-derived mesenchymal stem cell active growth factor and exosome product that is anticipated to revolutionize regenerative medicine.

In this study, Extracellular Vesicle Isolate Product (EVIP) was injected into 33 retired Navy SEALs to assist with knee, shoulder, elbow, ankle, and wrist osteoarthritis. At three-month follow-up, the injection appeared both safe and effective, with improvements ranging from 40% to as high as 98%. The average improvement is over 70%.

"This is extremely promising and we are motivated to continue our clinical studies to improve the quality of life for patients," says Kenneth Pettine.

Kenneth Pettine notes in his study that over 50 million Americans require daily treatment for disability and pain associated with OA. Every year, over one million total hip and knee replacements are performed in the U.S. with direct costs of over $30 billion and indirect costs of over $200 billion, with these numbers expected to double in the next three years.

In addition to this trial, Kenneth Pettine has three additional clinical studies planned to evaluate his stem cell products to treat erectile dysfunction, chronic obstructive pulmonary disease (COPD), and chronic lower back pain from painful discs.

For more information, visit https://www.kenneth-pettine.com/

About Kenneth Pettine

Dr. Kenneth Pettine is a serial entrepreneur and published clinical researcher with over 30 years of experience as an orthopedic surgeon. He holds a medical degree from the University of Colorado School of Medicine and completed his master's degree in orthopedic surgery and residency at the Mayo Clinic in Rochester, Minnesota.

In 1991, Dr. Pettine founded the Rocky Mountain Associates in Orthopedic Medicine. Kenneth Pettine is also the founder of Paisley Laboratories and the co-founder of the Society for Ambulatory Spine Surgery. In addition, he co-invented the Prestige cervical artificial disc and the Maverick Artificial Disc. Dr. Pettine is the principal investigator of 18 FDA studies involving non-fusion implants, biologics, and stem cells. He holds the only two issued U.S. patents for performing stem cell joint and spinal injections and currently has 21 additional patents pending for bone marrow derived mesenchymal stem cell applications. Kenneth Pettine is also a philanthropist and currently has a scholarship program underway to help students fund their education.

For more information, visit https://www.kenneth-pettine.com/ or https://www.kennethpettinescholarship.com/

Contact

info@kenneth-pettine.com

https://www.kenneth-pettine.com/

SOURCE: Kenneth Pettine

View source version on accesswire.com: https://www.accesswire.com/574987/Dr-Kenneth-Pettine-Announces-Verification-of-Clinical-Safety-Trial

More here:
Dr. Kenneth Pettine Announces Verification of Clinical Safety Trial - Yahoo Finance

The Marsh Presents Welcome to The Cancer Caf – Patch.com

By Stem Cell Clinic

BERKELEY, CA (3 February 2020) A PT Clinical Specialist in Chronic Pain, Judith C. never imagined being on the opposite end of treatment until she was diagnosed with Multiple Myeloma, an incurable blood cancer with a limited life expectancy. This March, Judith's journey from diagnosis to stem cell transplant unfolds in her hilarious and heartbreaking solo show Welcome to The Cancer Caf at The Marsh Berkeley. Enlightening, elevating, and deeply personal, Judith brings audiences on her unexpected journey from provider to patient, sharing the profound lessons this role reversal offers. Using actual conversations with providers, Judith portrays her interactions with the medical establishment, bringing keen insight and offering a better understanding of the journey and choices faced by people of similar circumstances. Proceeds from each show will be donated to a local cancer organization chosen by Judith. Talkback engagements after every performance will also be offered. Welcome to The Cancer Caf will be presented March 8 22, 2020 with performances at 2:00pm Sundays at The Marsh Berkeley, 2120 Allston Way, Berkeley. For tickets ($20-$35 sliding scale; $55 and $100 reserved) or more information, the public may visit http://www.themarsh.org or call The Marsh Box office at 415-282-3055 (open Monday through Friday, 1:00pm-4:00pm).

Motivated by portrayals of cancer heroes, cancer miracles, and people that "fight" for their lives, Judith C. was determined to shed light on different responses to cancer than the typical warrior model. Welcome to The Cancer Caf has been performed at the Stanford Oncology Grand Rounds (2017), Bone Marrow Transplant Life Survivorship Symposium in Denver, CO (2018) and Orlando, FL (2019), Kehilla Community Synagogue (2018), and for various cancer support groups throughout Northern CA. Originally presented at The Marsh Berkley as part of its Marsh Rising series in November 2019, Welcome to The Cancer Caf returns in March 2020 for a full run.

Proceeds from each performance will be donated to a local cancer organization chosen by Judith. Talkback engagements following all performances of Welcome to The Cancer Caf will also be offered:

Sunday, March 8: Proceeds will go towards Camp Kesem (Berkeley), one of many chapters of a wider organization that supports children through and beyond a parent's cancer. Founded at Stanford University in 2000, Camp Kesem has since expanded to 116 chapters in 42 states around the country, offering free summer camps for children who have been impacted by this life-changing event. Camp Kesem Outreach Coordinator Autumn Frlekin and Development Coordinator Shaked Salem will discuss how the camp brings together a community of children with similar experiences in a safe, welcoming environment to have fun and rediscover their childhood.

Sunday, March 15: Charlotte Maxwell Complementary Clinic for Low-Income Women with Cancer in Oakland will be receiving proceeds from the March 15th performance. For 25 years, this free public health clinic and 501(c)(3) non-profit organization has provided integrative cancer care and supportive services that compliment mainstream cancer treatments. These services include acupuncture, herbs, homeopathy, bodywork, guided imagery, movement, and nutritional therapies. Dr. Loveleena Virk and Dr. Divya Chandrasekar, Palliative Care MDs at Kaiser Oakland, will discuss approaches that improve the quality of life of patients and their families facing the problem associated with life-threatening illness.

Sunday, March 22: Proceeds from the final performance will go towards the Women's Cancer Resource Center (WCRC) in Berkeley. This non-profit organization creates opportunities for women with cancer to improve their quality of life through education, supportive services, and practical assistance. Dolores Moorehead, WCRC Lead Client Navigator and Multicultural Client Support Clinician, will be accompanied by a client to share how this organization helps people with cancer navigate through the overwhelming health care system, allowing them to get the appropriate care and treatment they need.

Described by the San Francisco press as "the monologue maestro" and "the dean of solo performance," David Ford has been collaborating on new and unusual theater for decades and has been associated with The Marsh for most of that time. After seeing Welcome to the Cancer Caf, Ford said, "I've worked for 30 years with people who are writing and performing their own stories. In that time, I've heard a lot of people give witness to the trials of having a life-threatening disease. Judith C. goes further than anyone I've ever encountered. She gets the awful contrasts of fear and courage, agency and impotence, armor and vulnerability."

Judith C. (Actor/Writer) is a PT Clinical Specialist in Chronic Pain/Feldenkrais practitioner, with decades of clinical and teaching experience. At age 58, she was diagnosed with Multiple Myeloma, an incurable blood cancer with no clear, accepted treatment path. Following her diagnosis, Judith began writing and performing about her experience as a way to cope with her life as a Myeloma patient being the "new normal" eventually leading to the birth of her first solo work, Welcome to The Cancer Caf.

Rebecca Fisher (Director) is the creator of The Marsh's Writing Cabaret and the co-producer of the long-running Marsh series Tell it on Tuesday. Her solo performance work has been called "smart, challenging, and unmistakably affecting" by the San Francisco Chronicle and has won a San Francisco Best of Fringe award. She has directed solo shows in national fringe festivals, as well as Mark Kenward's Nantucket and Diane Barnes' My Stroke of Luck, both presented at The Marsh. Fisher was a teaching artist with The Lincoln Center affiliated arts education program in Bay Area schools and has directed theater camps with the Berkeley Playhouse/Julia Morgan Center for the Arts and The Marsh.

The Marsh is known as "a breeding ground for new performance." It was launched in 1989 by Founder and Artistic Director Stephanie Weisman, and now annually hosts more than 600 performances of 175 shows across the company's two venues in San Francisco and Berkeley. A leading outlet for solo performers, The Marsh's specialty has been hailed by the San Francisco Chronicle as "solo performances that celebrate the power of storytelling at its simplest and purest." The East Bay Times named The Marsh one of Bay Area's best intimate theaters, calling it "one of the most thriving solo theaters in the nation. The live theatrical energy is simply irresistible."

Read this article:
The Marsh Presents Welcome to The Cancer Caf - Patch.com

→←